Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.

Rebecca C Furze,Judit Molnar,Nigel J Parr, Faiz Ahmad, Yvette Henry, David Howe,Rajendra Singh,Martin Toal,Anna K Bassil,Sharon G Bernard,Robert P Davis,Adele Gibson, N Claire Maller,Catriona Sharp,David F Tough,Rab K Prinjha,Huw D Lewis

British journal of clinical pharmacology（2022）

引用 1|浏览14

暂无评分

摘要

These findings demonstrate selective targeting of monocytes in humans using the ESM approach and identify monocytopaenia as a novel outcome of ESM-HDACi treatment, with implications for potential benefit of these molecules in myeloid-driven diseases.

查看译文

关键词

ESM-HDAC391,histone deacetylase inhibitor,monocyte,monocytopaenia,myeloid,pharmacodynamics,pharmacokinetics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要